Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Giovanni Conti is active.

Publication


Featured researches published by Giovanni Conti.


Clinical Transplantation | 2007

Serological and genetic factors in early recurrence of IgA nephropathy after renal transplantation

Rosanna Coppo; Alessandro Amore; Monica Chiesa; Federica Lombardo; Paola Cirina; Simeone Andrulli; Patrizia Passerini; Giovanni Conti; Licia Peruzzi; Roberta Giraudi; Maria Messina; Giuseppe Paolo Segoloni; Claudio Ponticelli

Abstract:  Background:  The relative role of IgA anomalies and genetic factors in IgA nephropathy (IgAN) recurrence after transplantation has never been investigated in a single cohort.


Italian Journal of Pediatrics | 2017

The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse

Andrea Pasini; Elisa Benetti; Giovanni Conti; Luciana Ghio; Marta Lepore; Laura Massella; Daniela Molino; Licia Peruzzi; Francesco Emma; Carmelo Fede; Antonella Trivelli; Silvio Maringhini; Marco Materassi; Giovanni Messina; Giovanni Montini; Luisa Murer; Carmine Pecoraro; Marco Pennesi

This consensus document is aimed at providing an updated, multidisciplinary overview on the diagnosis and treatment of pediatric nephrotic syndrome (NS) at first presentation. It is the first consensus document of its kind to be produced by all the pediatric nephrology centres in Italy, in line with what is already present in other countries such as France, Germany and the USA. It is based on the current knowledge surrounding the symptomatic and steroid treatment of NS, with a view to providing the basis for a separate consensus document on the treatment of relapses. NS is one of the most common pediatric glomerular diseases, with an incidence of around 2–7 cases per 100000 children per year. Corticosteroids are the mainstay of treatment, but the optimal therapeutic regimen for managing childhood idiopathic NS is still under debate. In Italy, shared treatment guidelines were lacking and, consequently, the choice of steroid regimen was based on the clinical expertise of each individual unit. On the basis of the 2015 Cochrane systematic review, KDIGO Guidelines and more recent data from the literature, this working group, with the contribution of all the pediatric nephrology centres in Italy and on the behalf of the Italian Society of Pediatric Nephrology, has produced a shared steroid protocol that will be useful for National Health System hospitals and pediatricians. Investigations at initial presentation and the principal causes of NS to be screened are suggested. In the early phase of the disease, symptomatic treatment is also important as many severe complications can occur which are either directly related to the pathophysiology of the underlying NS or to the steroid treatment itself. To date, very few studies have been published on the prophylaxis and treatment of these early complications, while recommendations are either lacking or conflicting. This consensus provides indications for the prevention, early recognition and treatment of these complications (management of edema and hypovolemia, therapy and prophylaxis of infections and thromboembolic events). Finally, recommendations about the clinical definition of steroid resistance and its initial diagnostic management, as well as indications for renal biopsy are provided.


Journal of Nephrology | 2013

N-Acetylcysteine in hemodialysis diabetic patients resets the activation of NF-kB in lymphomonocytes to normal values.

Alessandro Amore; Marco Formica; Franca Giacchino; Graziella Gigliola; Franco Bonello; Giovanni Conti; Roberta Camilla; Rosanna Coppo

BACKGROUND Oxidative stress pathways are activated in diabetes, particularly when dialysis is required (DD). NF-kB is activated in this clinical condition. Since N-Acetyl-cysteine (NAC) is an anti-oxidant, we aimed at investigating its effect in modulating NF-kB activation in lymphomonocytes (PBMC) of DD patients. METHODS Twenty-five DD patients were enrolled in a cross-over designed study. Tests were performed at T0 and after one month (T1) of treatment with NAC and three months after NAC withdrawal. We assessed NF-kB activation by EMSA, levels of advanced oxidation protein products (AOPP) by spectral analysis, total antioxidant capacity (TAC) by colorimetry, and apoptosis by FACS. RESULTS At T0 a statistically significant increased activation of the subunits of NF-kB, p50/p65, was detected in PBMC of DD patients in comparison to controls (both P<.0001). After one month of NAC both p50-p50/p50-p65 dimers were significantly reduced (P<.004 and .006). Three months after drug withdrawal NF-kB increased again to basal levels (P<.002 and P<.001 vs. end of treatment with NAC). AOPP and TAC levels and the percentage of apoptotic PBMC revealed modifications in accordance with NFkB activation. In a multivariate linear regression model using delta AOPP as the dependent variable and delta p50-p50, delta TAC, and delta APO as independent variables, we found that all three dependent parameters all retained an independent correlation with delta AOPP. CONCLUSIONS Our data indicate in vivo a modulation by NAC of parameters indicating a redox imbalance in DD patients on hemodialysis. The use of NAC might suggest a potential clinical benefit.


Journal of clinical & translational endocrinology | 2016

Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease

Luca Visconti; Salvatore Benvenga; Antonio Lacquaniti; Valeria Cernaro; Annamaria Bruzzese; Giovanni Conti; Michele Buemi; Domenico Santoro

The spectrum of lipid disorders in chronic kidney disease (CKD) is usually characterized by high triglycerides and reduced high dense lipoprotein (HDL), associated with normal or slightly reduced low dense lipoprotein (LDL)-cholesterol. This dyslipidemia is associated with an increased risk for atherosclerotic cardiovascular disease. Keys for the cardiovascular risk reduction in these patients are lowering the number and modifying the composition of the cholesterol-carrying atherogenic lipoprotein particles. Statins have an important role in primary prevention of cardiovascular events and mortality in non-hemodialyzed CKD patients. The benefits in terms of progression of renal failure are contradictory. Patient education regarding dietary regimen should be part of the CKD clinical management.


Journal of Renal Nutrition | 2017

Cystic Fibrosis: A Risk Condition for Renal Disease

Domenico Santoro; Adele Postorino; Cristina Lucanto; Stefano Costa; Simona Cristadoro; Salvatore Pellegrino; Giovanni Conti; Michele Buemi; Giuseppe Magazzù; Guido Bellinghieri

OBJECTIVE Cystic fibrosis (CF) is the most common autosomal recessive disease affecting the Caucasian population, with a birth incidence ranging between 1:2,500 and 1:1,800. It is caused by mutations in the CF transmembrane regulator gene which is localized on 7 chromosomes. Renal disease is reported as a relatively rare complication in adult patient with CF. We evaluated proteinuria and chronic renal failure (CRF) in a population of patients with CF. METHODS A retrospective study was carried out in a referral center for CF at University of Messina in Italy. We identified all patients with renal disease, characterized by proteinuria and/or CRF, during the period 2007 to 2012 and reviewed their medical records to assess influence on renal disease of genotype, number of pulmonary exacerbation, pancreatic insufficiency, pulmonary function, CF-related diabetes, and antibiotics courses. RESULTS From a population of 77 adult patients with CF, we identified 9 patients with proteinuria (11.7%), and 11 patients (14.28%) with CRF. Mean age was 35.6 (+5.1 standard deviation) years, 55% were female and 33% had diabetes mellitus. Renal biopsy was performed in 3 patients because of nephrotic syndrome in 1 patient and proteinuria with renal failure in the other 2 patients. Renal amyloidosis was disclosed in 2, whereas IgA nephropathy in 1 patient. The ΔF508 mutation in homozygosis was present in 44% of patients with proteinuria (vs. 27% of our CF population, relative risk 2.07), whereas genotype ΔF508/N1303K in 22%. ΔF508 allele mutation was present in 77.7% of proteinuric patients. CONCLUSIONS Our study shows a higher prevalence of renal disease in patients with CF, than was previously described. The main reason may be related to increased life expectancy because of better management. Moreover, patients with ΔF508 homozygosis had higher risk of proteinuria.


Case reports in pediatrics | 2017

Mixed Botryoid and Spindle Cell Bladder Rhabdomyosarcoma: An Outstanding Pediatric Case

Tommaso Alterio; Roberto Chimenz; Salvatore Arena; Giovanni Conti; Sabrina Cardile; Carmelo Romeo; Carmelo Salpietro; Carmelo Fede

We report a case of a 3-year-old North African child, initially assessed for nonspecific urinary symptoms such as haematuria and burning urination. The ultrasound evaluation showed a vegetating mass occupying the lumen with weak vascular signs at the Colour-Doppler evaluation. An explorative cystoscopy was performed and it revealed a nonbleeding lesion, white in colour, pedunculated, projecting into the lumen, and associated with a brown satellite formation. Histological examination showed a mixed Botryoid and Spindle Cell Rhabdomyosarcoma. This mixed histology has not been described before and no statistical data are reported in literature so far. Despite the Embryonal Rhabdomyosarcoma variant being the most common, the association characterized by two histological Rhabdomyosarcoma subtypes such as Botryoid and Spindle Cell is rarely observed and it is important to get an accurate histological diagnosis in order to immediately start the correct treatment protocol.


American Journal of Kidney Diseases | 2006

Predictors of Outcome in Henoch-Schönlein Nephritis in Children and Adults

Rosanna Coppo; Simeone Andrulli; Alessandro Amore; Bruno Gianoglio; Giovanni Conti; Licia Peruzzi; Francesco Locatelli; Leonardo Cagnoli


Journal of The American Society of Nephrology | 2001

Glycosylation of Circulating IgA in Patients with IgA Nephropathy Modulates Proliferation and Apoptosis of Mesangial Cells

Alessandro Amore; Paola Cirina; Giovanni Conti; Paola Brusa; Licia Peruzzi; Rosanna Coppo


American Journal of Kidney Diseases | 2000

Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells

Alessandro Amore; Giovanni Conti; Paola Cirina; Licia Peruzzi; Mirella Alpa; Federico Bussolino; Rosanna Coppo


Nephrology Dialysis Transplantation | 2003

Glucose degradation products increase apoptosis of human mesothelial cells

Alessandro Amore; Giorgio Cappelli; Paola Cirina; Giovanni Conti; Caterina Gambaruto; L Silvestro; Rosanna Coppo

Collaboration


Dive into the Giovanni Conti's collaboration.

Top Co-Authors

Avatar

Alessandro Amore

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Licia Peruzzi

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Rosanna Coppo

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rosanna Coppo

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge